April 2, 2021 — iCAD, Inc. introduced that ProFound AI for 2D Mammography may notably scale back the danger of interval breast most cancers, in keeping with a retrospective evaluation not too long ago printed within the Journal of Medical Screening.
The purpose of the research was to find out if including artificial intelligence (AI) to studying mammography as a supportive instrument could assist in reducing the interval most cancers price in population-based organized mammography screening applications in Germany.
“Interval breast cancers—cancers that are diagnosed after a negative mammography screening, but before the next recommended screening exam, can be linked to a poor prognosis such as cancer that has already spread, or a more aggressive type of cancer, thus underscoring the need for iCAD’s deep-learning algorithm that can analyze each mammography image and provide critical insight into individual cases,” mentioned Michael Klein, Chairman and CEO of iCAD. “The data from this retrospective analysis are very encouraging in Europe while also having an impact on screening in the US. The results further stress the importance of our ProFound AI platform as a world-class artificial intelligence (AI) solution offering benefits to radiologists and women in improving breast cancer detection rates, reducing false positives and unnecessary callbacks, and providing more personalized screening for every woman.”
In the retrospective evaluation, which evaluated a screening interval from 2011 and 2012, a complete of 37,367 girls between the ages of 50-69 had been screened with full-field digital mammography (FFDM). Of these, 29 circumstances of interval cancers with full documentation had been evaluated utilizing ProFound AI for 2D Mammography. For high quality assurance, interval cancers with the prior screening mammogram had been labeled in 4 classes by the radiologists: true interval cancers, minimal signal cancers, missed cancers (false unfavorable) primarily based on the unique screening examination deemed as regular and dismissed, and occult cancers. The goal of the research was to find out whether or not ProFound AI for 2D Mammography may determine interval cancers that had both minimal indicators within the authentic regular screening or had been missed within the authentic screening spherical the place they’d been dismissed as a traditional examination.
According to the lead creator of the research, Axel Gräwingholt, M.D., Radiologie am Theater in Paderborn, Germany, “The results indicate that ProFound AI for 2D Mammography found 93% of these cancers—eight out of nine cancers that presented minimal signs and six out of six that were false negatives, or missed in the screening round—demonstrating that some cancers could have been detected earlier within the screening round where they were dismissed as normal and therefore wouldn´t have been detected as interval cancers.”
“As a result, ProFound AI as a clinical tool for radiologists has the potential to reduce interval cancer rates by detecting cancers that are already present in the screening round but are perhaps undetected or missed by the readers,” continued Dr. Gräwingholt. “Using this technology at the screening level could limit the number of false negatives and help to detect a large proportion of the minimal sign cancers, which could ensure earlier treatment and better chances of recovery for these women.”
“This study contributes to the growing body of evidence that demonstrates the clear value ProFound AI for 2D Mammography can offer to screening programs across Europe, benefiting both the patient and the clinician,” mentioned Michele Debain, Vice President of Europe, Middle East and Africa at iCAD. “It is essential to detect breast cancers as early as possible, as the cancer can grow, develop and spread. Earlier cancer detection allows for earlier treatment, which in turn could lead to less stress for the patient and lower costs for the national health systems. In addition, the rate of interval cancers is typically used as a measure for the quality of the national mammography screening program.”
iCAD’s Breast Health Solutions suite consists of ProFound AI for Digital Breast Tomosynthesis (DBT) and software program options for 2D mammography, danger analysis and breast density. In 2018, ProFound AI for DBT acquired its CE mark, Health Canada approval and was the primary 3D tomosynthesis software program utilizing AI to obtain clearance from the U.S. Food and Drug Administration (FDA). ProFound AI for 2D Mammography acquired a CE mark in July 2019. In a reader research printed in Radiology, ProFound AI for DBT was proven to supply clinically confirmed time-savings advantages to radiologists, lowering studying time by 52.7 %, enhancing radiologist sensitivity by eight %, and lowering false positives and pointless affected person recall charges by 7.2 %.
For extra info: www.icadmed.com